Moderna and CytomX have entered into a collaboration and licensing agreement, worth up to US$1.2 B, to develop investigational mRNA-based conditionally activated therapies for cancer. Through the deal, the companies will leverage both Moderna’s mRNA technologies and CytomX’s Probody® therapeutic platform. The deal marks the end of a busy week for Moderna, following the announcement of its takeover of Japanese DNA supplier OriCiro Genomics for US$85 M, marking the biotech’s first acquisition.